BioStreamline
Creating a more agile timeline in biologics development
BioStreamline extended to work on next generation therapies
The BioStreamline project brings a unique approach to mitigating biotherapeutic development challenges using state of the art technologies to provide developers with a better understanding of candidate molecules earlier in the development process. This should allow developers to make better informed development decisions about which molecules to progress in development — reducing risk, cost and time.
BioStreamline (a 3 year project, total value of £11.2M) focussed on the supply chain for monoclonal antibodies. The project was made up of six partners from all sections of the drug development pipeline and supported by funding from the UK Government’s Advanced Manufacturing Supply Chain Initiative (AMSCI). The six partners included Lonza Biologics, UCB Celltech, Sphere Fluidics, Horizon Discovery, Alcyomics Ltd and CPI. By bringing together global companies from across different cutting-edge areas, the project gained complementary assets and expertise from each of the partners.
Partners
![UCB Pharma](https://optimise2.assets-servd.host/smart-hoopoe/production/content/logos/ucb-pharma-logo.jpg?w=400&h=403&q=100&fm=png&fit=crop&dm=1577983785&s=84664e5ce1742f5589d7886d19d9abca)
![Sphere Fluidics](https://optimise2.assets-servd.host/smart-hoopoe/production/content/logos/sphere-fluidics-logo.png?w=240&h=106&q=75&fm=png&fit=crop&dm=1577983870&s=4bed1a1af92521f6ceb0fe2e2f2b97c0)
![Alcyomics](https://optimise2.assets-servd.host/smart-hoopoe/production/content/logos/alcyomics-logo.png?w=400&h=88&q=100&fm=png&fit=crop&dm=1577983909&s=381be46fd4897be12ef19fbe2ba82762)
![Finance Birmingham](https://optimise2.assets-servd.host/smart-hoopoe/production/content/logos/finance-birmingham-logo.png?w=240&h=74&q=75&fm=png&fit=crop&dm=1577983926&s=aa1eb662d7078b58ecd0b454dfbf8d95)
![Department for Business, Energy and Industrial Strategy](https://optimise2.assets-servd.host/smart-hoopoe/production/content/logos/department-for-business-energy-and-industrial-strategy.png?w=400&h=212&q=100&fm=png&fit=crop&dm=1577983961&s=9acc86cab6258ca6597b3d45a095db56)
![Horizon](https://optimise2.assets-servd.host/smart-hoopoe/production/content/logos/Horizon-logo.jpg?w=400&h=209&q=100&fm=png&fit=crop&dm=1577984017&s=ff161427dfa37cb0264237843b1d2bfa)
Achievements
Inputs
- Provided open access to CPI’s state-of-the-art facilities
- Shared expert technical and industry knowledge
- Provided project management and business support services for publicly funded R&D projects
Outputs
- Development of a new single cell analysis system (Cyto-Mine™)
- New approaches to cell line development using CRISPR allowing rational inclusion of specific cell line features
- Developability data (biochemical, biophysical, stability) from a defined a panel of 50+ mAb (selected from a panel of 200+ mAb sequences) and generation of decisional tool
- Investigation of easy to implement, preclinical assessment of immunogenicity risks
Outcomes
- Decisional tool to support molecule development assessment
- New products and approaches available for shortening cell line development
- Database of molecule information for developability assessment and further investigation by advanced data analytics
- Exemplification of collaborative project approach which would be applicable to other therapeutic modalities including viral vectors
![](https://optimise2.assets-servd.host/smart-hoopoe/production/content/images/CPI_BIOLOGICS22.jpg?w=1920&h=1080&q=60&fm=jpg&fit=crop&dm=1559222697&s=109f91654569d5675f8b1dd2b5868850 1920w, https://optimise2.assets-servd.host/smart-hoopoe/production/content/images/CPI_BIOLOGICS22.jpg?w=1120&h=630&q=60&fm=jpg&fit=crop&dm=1559222697&s=da14f1ce1018b4e32def1fe7e81b83be 1120w, https://optimise2.assets-servd.host/smart-hoopoe/production/content/images/CPI_BIOLOGICS22.jpg?w=800&h=450&q=60&fm=jpg&fit=crop&dm=1559222697&s=2e8048add27cc74e3896c4c88ec2fa30 800w, https://optimise2.assets-servd.host/smart-hoopoe/production/content/images/CPI_BIOLOGICS22.jpg?w=1600&h=900&q=45&fm=jpg&fit=crop&dm=1559222697&s=b14f6339dd6a4a8484c39d8be3427988 1600w, https://optimise2.assets-servd.host/smart-hoopoe/production/content/images/CPI_BIOLOGICS22.jpg?w=480&h=270&q=60&fm=jpg&fit=crop&dm=1559222697&s=74263bb0c974550db2778346c68346a7 480w, https://optimise2.assets-servd.host/smart-hoopoe/production/content/images/CPI_BIOLOGICS22.jpg?w=960&h=540&q=45&fm=jpg&fit=crop&dm=1559222697&s=a08f306636da36203f3e88770752d3f7 960w)
The challenge
CPI was involved from the conception of the project through planning, partner selection and delivery. The challenge being addressed is that the biopharmaceutical industry has badly needed a more efficient supply chain that enables it to make predictions about the problems associated with developing new biotherapeutics reducing the risk and cost of commercialisation.
How CPI helped
As well as managing the project CPI inputs involved use of their expertise and facilities to generate samples of the 50+ shortlisted panel of monoclonal antibodies, generation of biochemical, biophysical and stability data on the molecules as well as data analysis.
Related
Technologies
Markets
![](https://optimise2.assets-servd.host/smart-hoopoe/production/content/images/vial.jpg?w=1920&h=1080&q=60&fm=jpg&fit=crop&dm=1559215828&s=0371899522bc2e1dba9f571de7ae2ab7 1920w, https://optimise2.assets-servd.host/smart-hoopoe/production/content/images/vial.jpg?w=1120&h=630&q=60&fm=jpg&fit=crop&dm=1559215828&s=59b1bbe29d7a230d1842089f4940a529 1120w, https://optimise2.assets-servd.host/smart-hoopoe/production/content/images/vial.jpg?w=2240&h=1260&q=45&fm=jpg&fit=crop&dm=1559215828&s=4a12056466a58b0480a47a4f19d4fb09 2240w, https://optimise2.assets-servd.host/smart-hoopoe/production/content/images/vial.jpg?w=800&h=450&q=60&fm=jpg&fit=crop&dm=1559215828&s=0a1a624782c8bfb2c89da40bfdeeb770 800w, https://optimise2.assets-servd.host/smart-hoopoe/production/content/images/vial.jpg?w=1600&h=900&q=45&fm=jpg&fit=crop&dm=1559215828&s=d0737ac2ed9466ed0e2b890fc7c268e9 1600w, https://optimise2.assets-servd.host/smart-hoopoe/production/content/images/vial.jpg?w=480&h=270&q=60&fm=jpg&fit=crop&dm=1559215828&s=7c7f26223e6dec4ebdbb4e9dbbf89ffd 480w, https://optimise2.assets-servd.host/smart-hoopoe/production/content/images/vial.jpg?w=960&h=540&q=45&fm=jpg&fit=crop&dm=1559215828&s=eda9bba1d4e0b060c99b2845621a7e43 960w)